logo-loader
viewStarpharma Holdings Limited

Full interview: Starpharma moving to Phase Two after successful Phase One for DEP irinotecan

Starpharma (ASX: SPL-OTCQX: SPHRY) CEO, Dr Jackie Fairley joined Steve Darling from Proactive with news the company is now moving to Phase 2 for their DEP irinotecan drug. Phase One finding it met its objective of evaluating safety, tolerability, pharmacokinetics and preliminary efficacy data.

Dr Fairley also told Proactive about another drug the company is working on, SPL7013 and how it may help in the fight against COVID-19.

Quick facts: Starpharma Holdings Limited

Price: 1.075 AUD

ASX:SPL
Market: ASX
Market Cap: $400.5 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Redx Pharma PLC's Lisa Anson updates on lead asset RXC004 and increased...

Redx Pharma PLC's (LON:REDX) Lisa Anson recaps on its lead product RXC004 which is in a Phase I clinical trial and is part of a potentially breakthrough group of cancer drugs called Porcupine inhibitors. Anson also details the recent investment by its majority shareholder Redmile which has...

16 hours, 47 minutes ago

2 min read